Literature DB >> 24327544

Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.

Donata Verdelli1, Lucia Nobili, Katia Todoerti, Laura Mosca, Sonia Fabris, Marianna D'Anca, Elisa Pellegrino, Roberto Piva, Giorgio Inghirami, Chiara Capelli, Martino Introna, Luca Baldini, Raffaella Chiaramonte, Luigia Lombardi, Antonino Neri.   

Abstract

We explored the molecular mechanisms involved in the establishement of CMA-03/06, an IL-6-independent variant of the multiple myeloma cell line CMA-03 previously generated in our Institution. CMA-03/06 cells grow in the absence of IL-6 with a doubling time comparable with that of CMA-03 cells; neither the addition of IL6 (IL-6) to the culture medium nor co-culture with multipotent mesenchymal stromal cells increases the proliferation rate, although they maintain the responsiveness to IL-6 stimulation as demonstrated by STAT1, STAT3, and STAT5 induction. IL-6 independence of CMA-03/06 cells is not apparently due to the development of an autocrine IL-6 loop, nor to the observed moderate constitutive activation of STAT5 and STAT3, since STAT3 silencing does not affect cell viability or proliferation. When compared to the parental cell line, CMA-03/06 cells showed an activated pattern of the NF-κB pathway. This finding is supported by gene expression profiling (GEP) analysis identifying an appreciable fraction of modulated genes (28/308) in the CMA-03/06 subclone reported to be involved in this pathway. Furthermore, although more resistant to apoptotic stimuli compared to the parental cell line, CMA-03/06 cells display a higher sensibility to NF-κB inhibition induced by bortezomib. Finally, GEP analysis suggests an involvement of a number of cytokines, which might contribute to IL-6 independence of CMA-03/06 by stimulating growth and antiapoptotic processes. In conclusion, the parental cell-line CMA-03 and its variant CMA-03/06 represent a suitable model to further investigate molecular mechanisms involved in the IL-6-independent growth of myeloma cells.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24327544     DOI: 10.1002/gcc.22127

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

1.  Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation.

Authors:  Sang-Hoon Sin; Sun Ah Kang; Yongbaek Kim; Anthony Eason; Kelly Tan; Hyowon An; Dirk P Dittmer
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

2.  Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.

Authors:  Marta Lionetti; Marzia Barbieri; Katia Todoerti; Luca Agnelli; Simona Marzorati; Sonia Fabris; Gabriella Ciceri; Serena Galletti; Giulia Milesi; Martina Manzoni; Mara Mazzoni; Angela Greco; Giovanni Tonon; Pellegrino Musto; Luca Baldini; Antonino Neri
Journal:  Oncotarget       Date:  2015-09-15

3.  Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.

Authors:  Sabrina Manni; Marilena Carrino; Martina Manzoni; Ketty Gianesin; Sara Canovas Nunes; Matteo Costacurta; Laura Quotti Tubi; Paolo Macaccaro; Elisa Taiana; Anna Cabrelle; Gregorio Barilà; Annalisa Martines; Renato Zambello; Laura Bonaldi; Livio Trentin; Antonino Neri; Gianpietro Semenzato; Francesco Piazza
Journal:  Oncotarget       Date:  2017-02-28

4.  A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.

Authors:  Marta Lionetti; Marzia Barbieri; Katia Todoerti; Luca Agnelli; Sonia Fabris; Giovanni Tonon; Simona Segalla; Ingrid Cifola; Eva Pinatel; Pierfrancesco Tassone; Pellegrino Musto; Luca Baldini; Antonino Neri
Journal:  Oncotarget       Date:  2015-09-22

5.  Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.

Authors:  Michela Colombo; Serena Galletti; Gaetano Bulfamante; Monica Falleni; Delfina Tosi; Katia Todoerti; Elisa Lazzari; Leslie A Crews; Catriona H M Jamieson; Sara Ravaioli; Francesco Baccianti; Silvia Garavelli; Natalia Platonova; Antonino Neri; Raffaella Chiaramonte
Journal:  Oncotarget       Date:  2016-08-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.